$813 Million is the total value of Logos Global Management LP's 39 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 65.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $88,790,000 | +30.9% | 1,300,000 | -13.3% | 10.92% | -12.3% |
| CYTK | Sell | CYTOKINETICS INC | $82,365,000 | +19.8% | 1,700,000 | -2.9% | 10.13% | -19.7% |
| IDYA | Buy | IDEAYA BIOSCIENCES INC | $61,694,000 | +19.2% | 4,135,000 | +10.3% | 7.58% | -20.1% |
| Sell | VENTYX BIOSCIENCES INC | $48,793,000 | +72.5% | 1,397,680 | -39.6% | 6.00% | +15.6% | |
| DSGN | DESIGN THERAPEUTICS INC | $46,774,000 | +19.4% | 2,797,501 | 0.0% | 5.75% | -20.0% | |
| BCYC | Buy | BICYCLE THERAPEUTICS PLCsponsored ads | $46,520,000 | +63.1% | 2,000,000 | +17.6% | 5.72% | +9.3% |
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $38,689,000 | +29.0% | 350,000 | -12.5% | 4.76% | -13.5% |
| ALLK | New | ALLAKOS INC | $36,332,000 | – | 5,936,666 | +100.0% | 4.47% | – |
| KRTX | KARUNA THERAPEUTICS INC | $33,740,000 | +77.8% | 150,000 | 0.0% | 4.15% | +19.1% | |
| ARQT | Buy | ARCUTIS BIOTHERAPEUTICS INC | $29,143,000 | +36.8% | 1,525,000 | +52.5% | 3.58% | -8.4% |
| DYN | Sell | DYNE THERAPEUTICS INC | $29,049,000 | +45.8% | 2,287,321 | -21.1% | 3.57% | -2.3% |
| ALXO | Sell | ALX ONCOLOGY HLDGS INC | $28,436,000 | +12.1% | 2,971,352 | -5.3% | 3.50% | -24.9% |
| ISEE | New | IVERIC BIO INC | $26,910,000 | – | 1,500,000 | +100.0% | 3.31% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $25,815,000 | – | 250,000 | +100.0% | 3.17% | – |
| Buy | DICE THERAPEUTICS INC | $22,009,000 | +43.9% | 1,085,251 | +10.1% | 2.71% | -3.5% | |
| VRDN | New | VIRIDIAN THERAPEUTICS INC | $20,510,000 | – | 1,000,000 | +100.0% | 2.52% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $18,050,000 | – | 500,000 | +100.0% | 2.22% | – |
| IMCR | New | IMMUNOCORE HLDGS PLCads | $16,429,000 | – | 350,000 | +100.0% | 2.02% | – |
| FULC | FULCRUM THERAPEUTICS INC | $15,776,000 | +65.1% | 1,950,000 | 0.0% | 1.94% | +10.6% | |
| AKRO | New | AKERO THERAPEUTICS INC | $13,620,000 | – | 400,000 | +100.0% | 1.67% | – |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $11,118,000 | – | 850,000 | +100.0% | 1.37% | – |
| OLMA | OLEMA PHARMACEUTICALS INC | $10,333,000 | -32.2% | 3,743,875 | 0.0% | 1.27% | -54.6% | |
| TCDA | New | TRICIDA INC | $9,956,000 | – | 950,000 | +100.0% | 1.22% | – |
| ALT | New | ALTIMMUNE INC | $9,578,000 | – | 750,000 | +100.0% | 1.18% | – |
| BLU | New | BELLUS HEALTH INC NEW | $8,448,000 | – | 800,000 | +100.0% | 1.04% | – |
| KZR | KEZAR LIFE SCIENCES INC | $8,180,000 | +4.1% | 950,000 | 0.0% | 1.01% | -30.2% | |
| CMPS | New | COMPASS PATHWAYS PLCsponsored ads | $5,472,000 | – | 510,000 | +100.0% | 0.67% | – |
| GERN | New | GERON CORP | $4,680,000 | – | 2,000,000 | +100.0% | 0.58% | – |
| IPSC | Sell | CENTURY THERAPEUTICS INC | $4,550,000 | +13.7% | 460,075 | -3.5% | 0.56% | -23.8% |
| TCDA | New | TRICIDA INCput | $2,517,000 | – | 240,200 | +100.0% | 0.31% | – |
| VIGIL NEUROSCIENCE INC | $1,871,000 | +253.0% | 205,595 | 0.0% | 0.23% | +137.1% | ||
| CNTA | CENTESSA PHARMACEUTICALS PLCsponsored ads | $1,607,000 | -17.5% | 399,801 | 0.0% | 0.20% | -44.5% | |
| TIL | Sell | INSTIL BIO INC | $1,606,000 | -6.0% | 331,872 | -10.3% | 0.20% | -37.1% |
| SPRB | SPRUCE BIOSCIENCES INC | $1,370,000 | -21.3% | 1,000,000 | 0.0% | 0.17% | -47.3% | |
| Sell | TYRA BIOSCIENCES INC | $1,119,000 | -6.0% | 127,316 | -23.5% | 0.14% | -37.0% | |
| Sell | LIANBIOsponsored ads | $616,000 | -27.7% | 307,908 | -21.9% | 0.08% | -51.3% | |
| TALS | Sell | TALARIS THERAPEUTICS INC | $521,000 | -57.4% | 197,913 | -27.0% | 0.06% | -71.4% |
| PYXIS ONCOLOGY INC | $434,000 | -17.3% | 220,434 | 0.0% | 0.05% | -44.8% | ||
| NUVBWS | NUVATION BIO INC*w exp 07/07/202 | $13,000 | -31.6% | 66,666 | 0.0% | 0.00% | -33.3% | |
| Exit | NUVALENT INC | $0 | – | -33,887 | -100.0% | -0.08% | – | |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -220,000 | -100.0% | -0.12% | – |
| EWTX | Exit | EDGEWISE THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.22% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -650,000 | -100.0% | -1.68% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -600,000 | -100.0% | -2.73% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -350,000 | -100.0% | -5.12% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -300,000 | -100.0% | -5.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 14 | Q3 2023 | 12.6% |
| KARUNA THERAPEUTICS INC | 14 | Q3 2023 | 5.6% |
| ALX ONCOLOGY HLDGS INC | 13 | Q3 2023 | 23.3% |
| DYNE THERAPEUTICS INC | 13 | Q3 2023 | 4.9% |
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 12.4% |
| OLEMA PHARMACEUTICALS INC | 12 | Q3 2023 | 15.4% |
| DESIGN THERAPEUTICS INC | 11 | Q3 2023 | 8.0% |
| NUVATION BIO INC | 11 | Q3 2023 | 0.0% |
| BICYCLE THERAPEUTICS PLC | 10 | Q2 2023 | 5.7% |
| IDEAYA BIOSCIENCES INC | 9 | Q3 2023 | 9.5% |
View Logos Global Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 18, 2023 | 6,350,000 | 8.1% |
| BICYCLE THERAPEUTICS plc | February 14, 2023 | 1,435,000 | 4.8% |
| Dyne Therapeutics, Inc. | February 14, 2023 | 2,150,000 | 4.1% |
| Design Therapeutics, Inc. | March 31, 2022 | 2,797,501 | 5.0% |
| IDEAYA Biosciences, Inc. | March 18, 2022 | 2,650,000 | 6.9% |
| Aligos Therapeutics, Inc. | February 14, 2022 | ? | ? |
| Cogent Biosciences, Inc. | February 14, 2022 | 150,000 | 0.4% |
| Kezar Life Sciences, Inc. | February 14, 2022 | 1,450,000 | 3.0% |
| Nkarta, Inc. | February 14, 2022 | ? | ? |
| Viridian Therapeutics, Inc.\DE | February 14, 2022 | ? | ? |
View Logos Global Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-01 |
| SC 13G | 2024-02-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-22 |
| SC 13G | 2024-01-02 |
View Logos Global Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.